Railway Pension Investments Ltd Lowers Position in Stryker Corporation $SYK

Key Points

• Railway Pension Investments cut its Stryker position by 16.8% in the second quarter, selling 82,040 shares and retaining 407,720 shares valued at approximately $128.4 million. Institutional investors own 77.09% of the company.
• Stryker reported quarterly earnings of $3.69 per share, exceeding estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, representing a 1.1% yield.
• Analysts maintain a generally positive outlook, with Stryker carrying a consensus rating of “Moderate Buy” and an average price target of $386.28, despite several recent target-price reductions.

Railway Pension Investments Ltd lowered its position in Stryker Corporation (NYSE:SYK - Free Report) by 16.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 407,720 shares of the medical technology company's stock after selling 82,040 shares during the period. Stryker comprises approximately 1.6% of Railway Pension Investments Ltd's holdings, making the stock its 26th largest position. Railway Pension Investments Ltd owned 0.11% of Stryker worth $128,367,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Stryker in the 4th quarter valued at about $1,822,272,000. Bank of America Corp DE bought a new stake in shares of Stryker during the second quarter valued at approximately $1,404,284,000. Auto Owners Insurance Co raised its position in Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of Stryker in the 2nd quarter worth $707,212,000. Finally, Jupiter Topco LLC bought a new stake in shares of Stryker in the second quarter valued at about $681,581,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

NYSE:SYK opened at $324.32 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a market capitalization of $124.40 billion, a P/E ratio of 33.61, a PEG ratio of 2.11 and a beta of 0.76. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a 50 day moving average price of $329.49 and a 200 day moving average price of $331.03.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is 36.48%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SYK shares. Citigroup restated a "buy" rating on shares of Stryker in a report on Thursday, August 13th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a research report on Friday, July 31st. JPMorgan Chase & Co. cut their target price on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. BTIG Research decreased their target price on Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a report on Friday, July 31st. Finally, Royal Bank Of Canada dropped their price objective on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating on the stock in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Insider Buying and Selling

In other news, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock worth $118,197,701 in the last ninety days. 4.60% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source